Zanubrutinib shows sustained superior PFS ... Innovators Network Endowed Chair and an associate professor in the Clinical Research Division at Fred Hutch Cancer Center, and an associate professor ...

The inclusion of new entities and the deletion of outdated ones reflect ongoing research and clinical observations ... inhibitors, zanubrutinib and ibrutinib, for patients with relapsed or ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

and now we have enrolled more than 1300 patients across the overall clinical trial program. At ASH, we presented the data from the phase 1 study that is a combination of zanubrutinib and sonrotoclax.

Prelude Therapeutics (PRLD) Incorporated announced the presentation of the first interim clinical data from its ongoing open-label, dose-escalation trial of PRT2527, a potent and highly selective ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.

Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (ONC – Research Report), boosting the price target to ...

AstraZeneca has received approval from the FDA for its BTK inhibitor, Calquence (acalabrutinib), for first-line use in MCL.

outpacing competitors such as BeiGene’s Brukinsa (zanubrutinib), Eli Lilly’s Jaypirca (pirtobrutinib), InnoCare’s Inokai (orelabrutinib), all of which remain in late-stage clinical trials ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific ... of immuno-oncology medicines to treat cancers. The company offers Zanubrutinib, a small molecule ...

“This is the first clinical trial, randomized clinical trial that ... acalabrutinib, or zanubrutinib). About half had also received an inhibitor of BCL-2 called venetoclax.